Article summary
The Court of Appeal has unanimously upheld the Competition and Markets Authority's (CMA) finding that Advanz broke competition law through excessive pricing of liothyronine tablets to the NHS between 2009-2017. The court reinstated the CMA's original £51.9m fine on private equity firm Cinven, which the Competition Appeal Tribunal had reduced to £37.1m in 2023. The total fines now stand at £99m, divided between Advanz (£40.9m), Cinven (£51.9m), and HgCapital (£6.2m). The ruling follows a three-day hearing in December 2024, where the court found no arguable basis to challenge the CMA's findings.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial